CL2019002003A1 - Azolopirimidina para el tratamiento de trastornos relacionados con cáncer. - Google Patents
Azolopirimidina para el tratamiento de trastornos relacionados con cáncer.Info
- Publication number
- CL2019002003A1 CL2019002003A1 CL2019002003A CL2019002003A CL2019002003A1 CL 2019002003 A1 CL2019002003 A1 CL 2019002003A1 CL 2019002003 A CL2019002003 A CL 2019002003A CL 2019002003 A CL2019002003 A CL 2019002003A CL 2019002003 A1 CL2019002003 A1 CL 2019002003A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- compound
- related disorders
- cancer
- azolopyrimidine
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 abstract 1
- 108010085273 Adenosine A2B receptor Proteins 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE DIVULGA UN COMPUESTO QUE ES UN INHIBIDOR DE POR LO MENOS UNO DE LOS RECEPTORES DE ADENOSINA A2A Y A2B, Y COMPOSICIONES QUE CONTIENEN EL COMPUESTO Y MÉTODOS PARA SINTETIZAR EL COMPUESTO. EL USO DE DICHO COMPUESTO Y COMPOSICIONES PARA EL TRATAMIENTO DE UNA GRAN DIVERSIDAD DE ENFERMEDADES, TRASTORNOS Y CONDICIONES, INCLUYENDO TRASTORNOS RELACIONADOS CON CÁNCER Y CON EL SISTEMA INMUNE QUE SON MEDIADOS, POR LO MENOS EN PARTE, POR EL RECEPTOR DE ADENOSINA A2A Y/O EL RECEPTOR DE ADENOSINA A2B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448608P | 2017-01-20 | 2017-01-20 | |
| US201762479005P | 2017-03-30 | 2017-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002003A1 true CL2019002003A1 (es) | 2019-11-29 |
Family
ID=62908757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002003A CL2019002003A1 (es) | 2017-01-20 | 2019-07-17 | Azolopirimidina para el tratamiento de trastornos relacionados con cáncer. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10399962B2 (es) |
| EP (2) | EP3570844B1 (es) |
| JP (4) | JP6697091B2 (es) |
| KR (1) | KR102611446B1 (es) |
| CN (2) | CN116768859A (es) |
| AU (3) | AU2018210272C1 (es) |
| CA (1) | CA3047600A1 (es) |
| CL (1) | CL2019002003A1 (es) |
| DK (1) | DK3570844T3 (es) |
| ES (1) | ES2971271T3 (es) |
| FI (1) | FI3570844T3 (es) |
| HR (1) | HRP20231157T1 (es) |
| HU (1) | HUE064141T2 (es) |
| IL (2) | IL267924B (es) |
| LT (1) | LT3570844T (es) |
| MX (2) | MX389798B (es) |
| MY (1) | MY202791A (es) |
| NZ (1) | NZ754731A (es) |
| PH (1) | PH12019501671A1 (es) |
| PL (1) | PL3570844T3 (es) |
| PT (1) | PT3570844T (es) |
| SA (1) | SA519402296B1 (es) |
| SG (1) | SG11201905812WA (es) |
| SI (1) | SI3570844T1 (es) |
| TW (2) | TWI781136B (es) |
| UA (1) | UA126863C2 (es) |
| UY (1) | UY37574A (es) |
| WO (1) | WO2018136700A1 (es) |
| ZA (1) | ZA202210004B (es) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2971271T3 (es) | 2017-01-20 | 2024-06-04 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer |
| DK3601296T3 (da) | 2017-03-30 | 2022-08-29 | iTeos Belgium SA | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere |
| RU2019133646A (ru) | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
| JP7189155B2 (ja) * | 2017-05-17 | 2022-12-13 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体 |
| US10793561B2 (en) | 2017-07-18 | 2020-10-06 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| KR102823186B1 (ko) * | 2018-02-16 | 2025-06-20 | 아르커스 바이오사이언시즈 인코포레이티드 | 아졸로피리미딘 화합물의 투여 |
| KR102826213B1 (ko) * | 2018-07-18 | 2025-06-27 | 아르커스 바이오사이언시즈 인코포레이티드 | 아졸로피리미딘 화합물의 고체 형태 |
| CN112601584A (zh) | 2018-07-24 | 2021-04-02 | 豪夫迈·罗氏有限公司 | 异喹啉化合物及其用途 |
| ES2982326T3 (es) * | 2018-07-27 | 2024-10-15 | Arcus Biosciences Inc | Antagonistas de la piridona A2R |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| IL281802B2 (en) | 2018-09-27 | 2025-10-01 | iTeos Belgium SA | Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist |
| BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| MA54298A (fr) * | 2018-11-30 | 2022-03-09 | Merck Sharp & Dohme | Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
| WO2020123444A1 (en) * | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| US11306071B2 (en) | 2019-01-18 | 2022-04-19 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN112996783B (zh) * | 2019-02-02 | 2022-11-18 | 江苏恒瑞医药股份有限公司 | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 |
| US12453738B2 (en) | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| AU2020256098A1 (en) * | 2019-03-29 | 2021-10-28 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| MY209362A (en) * | 2019-06-06 | 2025-07-03 | Arcus Biosciences Inc | Processes for preparing aminopyrimidine compounds |
| KR102443873B1 (ko) * | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | 피리미딘일 바이피리딘 화합물의 제조방법 및 그를 위한 중간체 |
| CN113121502A (zh) * | 2019-12-31 | 2021-07-16 | 山东铂源生物医药有限公司 | 一种杂芳烃类化合物、中间体、组合物及应用 |
| WO2021170797A1 (en) | 2020-02-26 | 2021-09-02 | iTeos Belgium SA | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS |
| CN113748110B (zh) * | 2020-03-16 | 2024-05-14 | 上海海雁医药科技有限公司 | 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
| EP4121409A1 (en) | 2020-03-19 | 2023-01-25 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| CN113429410B (zh) * | 2020-03-23 | 2022-10-04 | 上海海雁医药科技有限公司 | 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
| WO2021194326A1 (en) * | 2020-03-27 | 2021-09-30 | Dong-A St Co., Ltd. | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators |
| WO2021204626A1 (en) | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| CN116535365A (zh) | 2020-04-07 | 2023-08-04 | Iteos比利时公司 | 作为ent抑制剂用于治疗癌症的大环二胺衍生物以及其与腺苷受体拮抗剂的组合 |
| JP7776448B2 (ja) | 2020-06-02 | 2025-11-26 | アーカス バイオサイエンシズ インコーポレイティド | Ｔｉｇｉｔに対する抗体 |
| CN115942977A (zh) | 2020-06-17 | 2023-04-07 | 艾库斯生物科学有限公司 | Cd73抑制剂的结晶形式及其用途 |
| CN112812095A (zh) * | 2021-01-29 | 2021-05-18 | 成都安满生物医药科技有限公司 | 一种巴洛沙韦酯中间体的合成方法 |
| TW202245774A (zh) * | 2021-02-05 | 2022-12-01 | 大陸商上海齊魯製藥研究中心有限公司 | 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途 |
| EP4294948A1 (en) | 2021-02-17 | 2023-12-27 | iTeos Belgium SA | Compounds, compositions and methods of treatment thereof |
| KR102646627B1 (ko) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도 |
| WO2022236256A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| TW202313603A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl抑制劑化合物 |
| JP2024521706A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ化合物 |
| US20240376081A1 (en) * | 2021-09-15 | 2024-11-14 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof |
| WO2023040876A1 (zh) * | 2021-09-15 | 2023-03-23 | 上海海雁医药科技有限公司 | 氮杂芳环类化合物及其药学上可接受的盐的多晶型物、药物组合物和应用 |
| IL312348A (en) | 2021-10-29 | 2024-06-01 | Arcus Biosciences Inc | HIF-2ALPHA inhibitors and methods of using it |
| CN116063292A (zh) * | 2021-10-29 | 2023-05-05 | 山东晶源生物医药有限公司 | 一种含氮化合物、其中间体、其组合物、其制备方法及其应用 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| CN114907273B (zh) * | 2022-06-09 | 2025-02-18 | 乐威医药（江苏）股份有限公司 | 2-氨基嘧啶-6-芳基化合物的制备方法 |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4587001A1 (en) | 2022-09-14 | 2025-07-23 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| JP2025536309A (ja) | 2022-10-20 | 2025-11-05 | アーカス バイオサイエンシズ インコーポレイティド | Ｃｄ７３化合物の凍結乾燥製剤 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| WO2024134541A1 (en) | 2022-12-20 | 2024-06-27 | iTeos Belgium SA | Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025096979A1 (en) | 2023-11-02 | 2025-05-08 | Arcus Biosciences, Inc. | Thiazole compounds as kit inhibitors and methods of use thereof |
| TW202523332A (zh) | 2023-11-14 | 2025-06-16 | 比利時商艾托斯比利時公司 | Ｅｎｔ１抑制劑與檢查點抑制劑組合 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2025254418A1 (ko) * | 2024-06-03 | 2025-12-11 | 동아에스티 주식회사 | 아미노피리미딘 유도체의 결정다형 및 이의 제조방법 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| US7163923B2 (en) | 2001-05-09 | 2007-01-16 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
| TWI330183B (es) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| BRPI0417478A (pt) * | 2003-12-15 | 2007-05-08 | Almirall Prodesfarma Ag | 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CN101541783B (zh) * | 2006-06-30 | 2014-10-01 | 苏尼西斯制药有限公司 | 吡啶酮基pdk1抑制剂 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| WO2010059658A1 (en) | 2008-11-20 | 2010-05-27 | Glaxosmithkline Llc | Chemical compounds |
| ES2974437T3 (es) | 2008-12-09 | 2024-06-27 | Hoffmann La Roche | Anticuerpos ANTI-PD-L1 y su uso para mejorar la función de las células T |
| ES2788869T3 (es) | 2009-09-03 | 2020-10-23 | Merck Sharp & Dohme | Anticuerpos anti-GITR |
| EP2510010B1 (en) | 2009-12-10 | 2015-11-25 | F.Hoffmann-La Roche Ag | Antibodies binding to human CSF1R extracellular domain 4 and their use |
| CA2791658C (en) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| MX336682B (es) | 2010-03-05 | 2016-01-27 | Hoffmann La Roche | Anticuerpos contra csf-1r humanos y usos de los mismos. |
| CN112480256A (zh) | 2010-05-04 | 2021-03-12 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| JP6105470B2 (ja) | 2010-09-09 | 2017-03-29 | ファイザー・インク | ４−１ｂｂ結合分子 |
| DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130269017A1 (en) | 2012-04-04 | 2013-10-10 | Salesforce.Com, Inc. | Centralized single sign on service for websites and online services |
| KR20220162819A (ko) | 2012-05-11 | 2022-12-08 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CA2882804A1 (en) | 2012-08-31 | 2014-03-06 | Brian Wong | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN103664908A (zh) | 2013-12-10 | 2014-03-26 | 苏州大学 | 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物 |
| CN106749190B (zh) * | 2015-11-23 | 2019-05-17 | 苏州云轩医药科技有限公司 | 具有腺苷受体拮抗活性的氨基嘧啶杂环化合物及其应用 |
| ES2971271T3 (es) | 2017-01-20 | 2024-06-04 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
| RU2019133646A (ru) | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
-
2018
- 2018-01-19 ES ES18741044T patent/ES2971271T3/es active Active
- 2018-01-19 TW TW107101999A patent/TWI781136B/zh active
- 2018-01-19 SG SG11201905812WA patent/SG11201905812WA/en unknown
- 2018-01-19 KR KR1020197024140A patent/KR102611446B1/ko active Active
- 2018-01-19 LT LTEPPCT/US2018/014352T patent/LT3570844T/lt unknown
- 2018-01-19 DK DK18741044.4T patent/DK3570844T3/da active
- 2018-01-19 TW TW111136869A patent/TWI812494B/zh active
- 2018-01-19 HU HUE18741044A patent/HUE064141T2/hu unknown
- 2018-01-19 CN CN202310541174.8A patent/CN116768859A/zh active Pending
- 2018-01-19 US US15/875,106 patent/US10399962B2/en active Active
- 2018-01-19 MY MYPI2019003049A patent/MY202791A/en unknown
- 2018-01-19 SI SI201831021T patent/SI3570844T1/sl unknown
- 2018-01-19 CA CA3047600A patent/CA3047600A1/en active Pending
- 2018-01-19 PT PT187410444T patent/PT3570844T/pt unknown
- 2018-01-19 NZ NZ754731A patent/NZ754731A/en unknown
- 2018-01-19 UA UAA201909210A patent/UA126863C2/uk unknown
- 2018-01-19 CN CN201880007563.XA patent/CN110214012B/zh active Active
- 2018-01-19 EP EP18741044.4A patent/EP3570844B1/en active Active
- 2018-01-19 WO PCT/US2018/014352 patent/WO2018136700A1/en not_active Ceased
- 2018-01-19 UY UY0001037574A patent/UY37574A/es active IP Right Grant
- 2018-01-19 HR HRP20231157TT patent/HRP20231157T1/hr unknown
- 2018-01-19 EP EP23194932.2A patent/EP4310082A3/en active Pending
- 2018-01-19 AU AU2018210272A patent/AU2018210272C1/en active Active
- 2018-01-19 FI FIEP18741044.4T patent/FI3570844T3/fi active
- 2018-01-19 MX MX2019008593A patent/MX389798B/es unknown
- 2018-01-19 PL PL18741044.4T patent/PL3570844T3/pl unknown
- 2018-01-19 JP JP2018548449A patent/JP6697091B2/ja active Active
-
2019
- 2019-07-02 US US16/460,263 patent/US11072597B2/en active Active
- 2019-07-08 IL IL267924A patent/IL267924B/en unknown
- 2019-07-15 SA SA519402296A patent/SA519402296B1/ar unknown
- 2019-07-17 CL CL2019002003A patent/CL2019002003A1/es unknown
- 2019-07-18 MX MX2022001360A patent/MX2022001360A/es unknown
- 2019-07-19 PH PH12019501671A patent/PH12019501671A1/en unknown
-
2020
- 2020-04-23 JP JP2020076575A patent/JP7021282B2/ja active Active
-
2021
- 2021-10-22 US US17/507,921 patent/US12195447B2/en active Active
-
2022
- 2022-01-06 IL IL289650A patent/IL289650A/en unknown
- 2022-02-03 JP JP2022015648A patent/JP2022048352A/ja not_active Withdrawn
- 2022-05-24 AU AU2022203515A patent/AU2022203515B2/en active Active
- 2022-09-08 ZA ZA2022/10004A patent/ZA202210004B/en unknown
-
2024
- 2024-03-05 JP JP2024032994A patent/JP2024063179A/ja active Pending
- 2024-05-21 AU AU2024203366A patent/AU2024203366A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002003A1 (es) | Azolopirimidina para el tratamiento de trastornos relacionados con cáncer. | |
| UY37725A (es) | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CL2019003143A1 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso. | |
| PH12016502479A1 (en) | Formulated receptor polypeptides and related methods | |
| MX393818B (es) | Terapias de combinación para el tratamiento de cáncer. | |
| MX2016010080A (es) | Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer. | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2016013239A (es) | Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19. | |
| CL2018003444A1 (es) | Derivados de adenosina para uso en el tratamiento del cancer. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX2017013178A (es) | Terapia de combinacion para cancer. | |
| CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| MX2016011561A (es) | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. | |
| MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
| MX392545B (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos. | |
| MX385658B (es) | Inhibidores del receptor de glucocorticoides. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| ES3054839T3 (en) | Use of a nox4 or nox4/1 inhibitor in combination with an immunotherapeutic agent for the treatment of cancer |